Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Study of ELX-02 in adults with cystic fibrosis who have at least one G542X mutation , protocol number Eloxx EL-012

  This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X mutation.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    15

  • Length of Participation:

    15 weeks

• Anti-InflammatoryEnrolling

  Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa , protocol number Calithera CX-280-202

  This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    2 months

• Anti-InfectiveEnrolling

  STOP-PEDS Pilot: Study to evaluate treatment of pulmonary exacerbations in children 6-18 years old with CF , protocol number STOP-PEDS 2.0

  This study will evaluate children 6 to 18 years old with CF to determine the acceptability and feasibility of a larger trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation treatment.

  • Age:

    6 Years to 18 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50% or greater

  • Number of Visits:

    3

  • Length of Participation:

    18 months

• ObservationalEnrolling

  MAYFLOWERS: Study of pregnancy in women with cystic fibrosis , protocol number MAYFLOWERS-OB-20

  This observational study will evaluate the effects of CFTR modulators on women with CF during and after pregnancy. CFTR modulators are intended to help CFTR protein function closer to normal.

  • Age:

    16 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    9

  • Length of Participation:

    35 months

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.